BIOMARKER:

CDK12 mutation

Entrez ID:

Related biomarkers:

‹

›

CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab Sensitive: C2 – Inclusion Criteria
CDK12 mutation CDK12 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	AST-2970 Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	rucaparib Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	Immunotherapy Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials
CDK12 mutation CDK12 mutation	Non Small Cell Lung Cancer NSCLC	olaparib Sensitive: C4 – Case Studies
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies